HIV Research Section, San Francisco Department of Public Health, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102-6033, USA.
AIDS Behav. 2011 Apr;15 Suppl 1(Suppl 1):S72-9. doi: 10.1007/s10461-011-9894-1.
Pre-exposure prophylaxis (PrEP) for HIV prevention is a promising experimental approach currently being tested globally. A number of PrEP trials are evaluating the safety and effectiveness of PrEP in men who have sex with men (MSM) and other populations at risk for HIV, and results will be available from this first generation of efficacy trials over the next few years. Here we review the rationale for orally-administered antiretrovirals for prevention, and outline issues the first generation trials will address as well as questions that may be addressed in future studies. We also describe the rationale for combination prevention approaches that may combine PrEP with other prevention modalities as part of a larger prevention package.
暴露前预防（PrEP）是一种有前途的艾滋病预防方法，目前正在全球范围内进行测试。许多 PrEP 试验正在评估在男男性行为者（MSM）和其他艾滋病高危人群中使用 PrEP 的安全性和有效性，第一代疗效试验的结果将在未来几年内公布。在这里，我们回顾了口服抗逆转录病毒药物预防的原理，并概述了第一代试验将解决的问题以及未来研究中可能解决的问题。我们还描述了联合预防方法的原理，这些方法可以将 PrEP 与其他预防方式结合起来，作为一个更大的预防方案的一部分。
